Infusion site reactions: Classification in the setting of fosaprepitant administration with chemotherapy Journal Article


Authors: Segna, A. N.; Baron, R. H.; Cohen, B.
Article Title: Infusion site reactions: Classification in the setting of fosaprepitant administration with chemotherapy
Abstract: BACKGROUND: Studies report a wide range of incidence and severity of infusion site adverse events (ISAEs) following fosaprepitant administration. OBJECTIVES: The purposes of this study were (a) to determine the incidence of suspected extravasation in patients with cancer receiving fosaprepitant infusions with chemotherapy and (b) to determine whether the documented signs, symptoms, and management strategies aligned with the diagnostic criteria for extravasation versus non-extravasation ISAEs. METHODS: Electronic health records were used to identify patients who received fosaprepitant infusion with chemotherapy and had documentation for suspected extravasation. Chart reviews were conducted for a sample of patients to determine whether documentation was consistent with extravasation. FINDINGS: About 3% (n = 460 of 15,667) of patients who received fosaprepitant had documentation for suspected extravasation. Among a random sample of patients (N = 110) with suspected extravasation, 6% (n = 6) had documentation consistent with extravasation. © 2020, Oncology Nursing Society. All rights reserved.
Keywords: fosaprepitant; extravasation; antiemetic agents; vesicant chemotherapy
Journal Title: Clinical Journal of Oncology Nursing
Volume: 24
Issue: 6
ISSN: 1092-1095
Publisher: Oncology Nursing Society (ONS)  
Date Published: 2020-12-01
Start Page: E79
End Page: E84
Language: English
DOI: 10.1188/20.Cjon.E79-e84
PUBMED: 33216065
PROVIDER: scopus
PMCID: PMC8492072
DOI/URL:
Notes: Article -- Export Date: 4 January 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Roberta H Baron
    24 Baron
  2. Alexa N Segna
    2 Segna
  3. Bevin Cohen
    7 Cohen